Analysts' Top 5 Price Targets of July 31, 2025
Reading Time: 2 minutes
Ionis Pharmaceuticals Inc. [US4622221004] Morgan Stanley has raised its rating from Equal Weight to Overweight and adjusted the price target from $55 to $62 (41% upside potential) Morgan Stanley upgraded Ionis Pharmaceuticals from Equal Weight to Overweight and raised the price target from $55 to $62. According to the analyst, the company reported another quarter of exceeded expectations and raised guidance, supported by strong early sales trends of Tryngolza. The expert is now more convinced of Ionis's potential in the severe hypertriglyceridemia...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
